Abstract
High-risk non-muscle invasive bladder cancers (HRNMIBC), including TaG3, T1G2, T1G3, and/or Tis, carry an increased risk of progression, recurrence, and even death. The commonly used therapeutic approaches are TURBT+BCG or radical cystectomy (RC). So far, there have been no randomized clinical trials comparing the efficacy of these two different modalities. However, there continue to be some concerns regarding the long-term outcomes of the bladder preserving approach. Therefore, we conducted this meta-analysis to compare the relative risk (RR) of cancer-specific and all-cause death rates between TURBT+BCG and RC in HRNMIBC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
